BCL2 and chronic myelogenous leukemia, BCR-ABL1 positive: The observation that, in committed CML cells, BCL2 inhibition induced apoptosis, also increasing the BCR-ABL1 kinase inhibitor efficacy, implicates the role of BCL2 in the BCR-ABL1-mediated pro-survival activity.